絞り込み

16417

広告

Direct oral anticoagulants and its implications in dentistry. A review of literature.

著者 Lanau N , Mareque J , Giner L , Zabalza M
J Clin Exp Dent.2017 Nov ; 9(11):e1346-e1354.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Miscellaneous

Four novel direct oral anticoagulants (DOACs) named dabigatran, rivaroxaban, edoxaban and apixaban have been recently introduced to overcome some of the drawbacks of existing anticoagulants. They have less interactions and do not require routine monitoring. However, there is not enough scientific data about the protocol to apply in these patients on DOACs undergoing dental treatment. Thus is necessary to evaluate the potential bleeding risk of these drugs, the possibility of thromboembolic events occurring if they are withdrawn or the need to change to heparin previously.
PMID: 29302288 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード